We are live on ! Find out more
APGN

Apexigen, Inc. Common Stock

Delisted

APGN was delisted on the 22nd of August, 2023.

18 hedge funds and large institutions have $8.52M invested in Apexigen, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more call options, than puts

Call options by funds: $50K | Put options by funds: $45K

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

33% less funds holding

Funds holding: 2718 (-9)

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

77% less capital invested

Capital invested by funds: $37.5M → $8.52M (-$28.9M)

Holders
18
Holders Change
-9
Holders Change %
-33.33%
% of All Funds
0.31%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
1
Reduced
1
Closed
24
Calls
$50K
Puts
$45K
Net Calls
+$5K
Net Calls Change
+$5K

APGN Hedge Fund Activity: Q3 2022 in Review

18 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q3 2022, worth a combined $8.52M — down 77% from $37.5M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of APGN and 15 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Decheng Capital Management III (Cayman), opening a new position worth an estimated $15.4M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $4.71M sold.

  • 18 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q3 2022, down from 27 in Q2 2022.
  • Funds reported $8.52M of Apexigen, Inc. Common Stock stock for Q3 2022, down 77% quarter-over-quarter.
  • 15 funds opened new Apexigen, Inc. Common Stock positions in Q3 2022 and 24 closed out, a net change of -9 holders.
  • The largest Apexigen, Inc. Common Stock buyer in Q3 2022 was Decheng Capital Management III (Cayman), an estimated $15.4M added.
  • The largest Apexigen, Inc. Common Stock seller in Q3 2022 was Mizuho Securities USA, an estimated $4.71M sold.

Based on aggregated 13F filings for Q3 2022.